Moving in extreme environments:what’s extreme and who decides?

Humans work, rest and play in immensely varied extreme environments. The term ‘extreme’ typically refers to insufficiency or excess of one or more stressors, such as thermal energy or gravity. Individuals’ behavioural and physiological capacity to endure and enjoy such environments varies immensely. Adverse effects of acute exposure to these environments are readily identifiable (e.g. heat stroke or bone fracture), whereas adverse effects of chronic exposure (e.g. stress fractures or osteoporosis) may be as important but much less discernable. Modern societies have increasingly sought to protect people from such stressors and, in that way, minimise their adverse effects. Regulations are thus established, and advice is provided on what is ‘acceptable’ exposure. Examples include work/rest cycles in the heat, hydration regimes, rates of ascent to and duration of stay at altitude and diving depth. While usually valuable and well intentioned, it is important to realise the breadth and importance of limitations associated with such guidelines. Regulations and advisories leave less room for self-determination, learning and perhaps adaptation. Regulations based on stress (e.g. work/rest cycles relative to WBGT) are more practical but less direct than those based on strain (e.g. core temperature), but even the latter can be substantively limited (e.g. by lack of criterion validation and allowance for behavioural regulation in the research on which they are based). Extreme Physiology & Medicine is publishing a series of reviews aimed at critically examining the issues involved with self- versus regulation-controlled human movement acutely and chronically in extreme environments. These papers, arising from a research symposium in 2013, are about the impact of people engaging in such environments and the effect of rules and guidelines on their safety, enjoyment, autonomy and productivity. The reviews will cover occupational heat stress, sporting heat stress, hydration, diving, extreme loading, chronic unloading and high altitude. Ramifications include factors such as health and safety, productivity, enjoyment and autonomy, acute and chronic protection and optimising adaptation

Training on a Lower Body Positive Pressure Treadmill With Body Weight Support does not Improve Aerobic Capacity

International Journal of Exercise Science 14(7): 829-839, 2021. This study examined the physiological changes resulting from training on a lower body positive pressure treadmill (LBPPT) at three different levels of body weight support (BWS). Thirty-three healthy college aged students (22.3 ± 3.1 years) completed the study. Participants performed a graded exercise test (GXT) to exhaustion and were placed into one of three experimental groups corresponding to 100%, 75%, and 50% of their normal BW. Participants trained at their experimental BW levels for eight-weeks. Training speed was monitored by heart rate (HR) and speed was adjusted to elicit approximately 60% of participant’s peak oxygen uptake (V̇O2peak) at normal BW prior to including body weight support (BWS). One-way analysis of variance (ANOVA) was used to compare the change in aerobic capacity. The 100% BW group improved their relative V̇O2peak (1.42 ± 1.52 ml · min-1 · kg-1) when compared to the 50% BW group (-0.87 ± 2.20 ml · min-1 · kg-1 [p = .022]) but not the 75% BW group (-0.16 ± 1.92 ml · min-1 · kg-1, [p = .14]). Furthermore, no statistical differences in V̇O2peak were observed between the 75% and 50% BW groups (p = .66). Based on this study, training at 75% and 50% of normal BW on a LBPPT does not improve aerobic capacity compared to training with no BWS when using training speeds derived from a GXT with full BW. The outcome of this study may help to prescribe training speeds while utilizing a LBPPT to maintain or improve aerobic capacity

Editorial:Cross adaptation and cross tolerance in human health and disease

Human physiological responses to heat, cold, hypoxia, microgravity, hyperbaria, hypobaria and fasting are well studied in isolation. However, in the natural world these stressors are often combined or experienced sequentially (Tipton, 2012). Studies examining human responses to these more realistic, yet relatively complex, circumstances remain sparse, but could provide important insights into an emerging area within human physiology: cross-adaptation (Figure 1)(Lunt et al., 2010; Gibson et al., 2017). Much of the current state of knowledge involves data demonstrating benefits of exercising in hot conditions, prior to performance in hypoxia (Gibson et al., 2015; Heled et al., 2012; Lee et al., 2014a, 2014b, 2016; Salgado et al., 2017; White et al., 2016), with cold to hypoxia (Lunt et al., 2010), hypoxia to heat (Sotiridis et al., 2018), combined stressors (Neal et al., 2017; Takeno et al., 2001), and more mechanistic (signalling) data from animal models exposed to substantive volumes of stress (Maloyan & Horowitz, 2002, 2005). The role of nutrient availability and the nutrient-exercise interactions which drive phenotypic adaptations to skeletal muscle exposed to a multitude of stressors is also a growing field of interest (Hawley, Lundby, Cotter, & Burke, 2018). This research topic includes publications which address both clinical and exercise-centric aspects allied to Cross-adaptation and Cross-tolerance in Human Health and Disease

Use of semiconductor optical amplifiers in signal processing applications

We describe a 42.6 Gbit/s all-optical pattern recognition system which uses semiconductor optical amplifiers (SOAs). A circuit with three SOA-based logic gates is used to identify the presence of specific port numbers in an optical packet header

Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery

Objectives Persistent bowel dysfunction following gastroenteritis (postinfectious (PI)-BD) is well recognised, but the associated changes in microbiota remain unclear. Our aim was to define these changes after gastroenteritis caused by a single organism, Campylobacter jejuni, examining the dynamic changes in the microbiota and the impact of antibiotics. Design A single-centre cohort study of 155 patients infected with Campylobacter jejuni. Features of the initial illness as well as current bowel symptoms and the intestinal microbiota composition were recorded soon after infection (visit 1, 80 days later (visits 2 and 3). Microbiota were assessed using 16S rRNA sequencing. Results PI-BD was found in 22 of the 99 patients who completed the trial. The cases reported significantly looser stools, with more somatic and gastrointestinal symptoms. Microbiota were assessed in 22 cases who had significantly lower diversity and altered microbiota composition compared with the 44 age-matched and sex-matched controls. Moreover 60 days after infection, cases showed a significantly lower abundance of 23 taxa including phylum Firmicutes, particularly in the order Clostridiales and the family Ruminoccocaceae, increased Proteobacteria abundance and increased levels of Fusobacteria and Gammaproteobacteria. The microbiota changes were linked with diet; higher fibre consumption being associated with lower levels of Gammaproteobacteria. Conclusion The microbiota of PI-BD patients appeared more disturbed by the initial infection compared with the microbiota of those who recovered. The prebiotic effect of high fibre diets may inhibit some of the disturbances seen in PI-BD.Peer reviewe

Extensive migration of young neurons into the infant human frontal lobe.

The first few months after birth, when a child begins to interact with the environment, are critical to human brain development. The human frontal lobe is important for social behavior and executive function; it has increased in size and complexity relative to other species, but the processes that have contributed to this expansion are unknown. Our studies of postmortem infant human brains revealed a collection of neurons that migrate and integrate widely into the frontal lobe during infancy. Chains of young neurons move tangentially close to the walls of the lateral ventricles and along blood vessels. These cells then individually disperse long distances to reach cortical tissue, where they differentiate and contribute to inhibitory circuits. Late-arriving interneurons could contribute to developmental plasticity, and the disruption of their postnatal migration or differentiation may underlie neurodevelopmental disorders

Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2

OBJECTIVES: This study sought to better understand the discrepant results of 2 trials of serelaxin on acute heart failure (AHF) and short-term mortality after AHF by analyzing causes of death of patients in the RELAX-AHF-2 (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF-2) trial. BACKGROUND: Patients with AHF continue to suffer significant short-term mortality, but limited systematic analyses of causes of death in this patient population are available. METHODS: Adjudicated cause of death of patients in RELAX-AHF-2, a randomized, double-blind, placebo-controlled trial of serelaxin in patients with AHF across the spectrum of ejection fraction (EF), was analyzed. RESULTS: By 180 days of follow-up, 11.5% of patients in RELAX-AHF-2 died, primarily due to heart failure (HF) (38% of all deaths). Unlike RELAX-AHF, there was no apparent effect of treatment with serelaxin on any category of cause of death. Older patients (≥75 years) had higher rates of mortality (14.2% vs. 8.8%) and noncardiovascular (CV) death (27% vs. 19%) compared to younger patients. Patients with preserved EF (≥50%) had lower rates of HF-related mortality (30% vs. 40%) but higher non-CV mortality (36% vs. 20%) compared to patients with reduced EF. CONCLUSIONS: Despite previous data suggesting benefit of serelaxin in AHF, treatment with serelaxin was not found to improve overall mortality or have an effect on any category of cause of death in RELAX-AHF-2. Careful adjudication of events in the serelaxin trials showed that older patients and those with preserved EF had fewer deaths from HF or sudden death and more deaths from other CV causes and from noncardiac causes. (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778)

Cause of Death in Patients With Acute Heart Failure Insights From RELAX-AHF-2

OBJECTIVES: This study sought to better understand the discrepant results of 2 trials of serelaxin on acute heart failure (AHF) and short-term mortality after AHF by analyzing causes of death of patients in the RELAX-AHF-2 (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF-2) trial. BACKGROUND: Patients with AHF continue to suffer significant short-term mortality, but limited systematic analyses of causes of death in this patient population are available. METHODS: Adjudicated cause of death of patients in RELAX-AHF-2, a randomized, double-blind, placebo-controlled trial of serelaxin in patients with AHF across the spectrum of ejection fraction (EF), was analyzed. RESULTS: By 180 days of follow-up, 11.5% of patients in RELAX-AHF-2 died, primarily due to heart failure (HF) (38% of all deaths). Unlike RELAX-AHF, there was no apparent effect of treatment with serelaxin on any category of cause of death. Older patients (≥75 years) had higher rates of mortality (14.2% vs. 8.8%) and noncardiovascular (CV) death (27% vs. 19%) compared to younger patients. Patients with preserved EF (≥50%) had lower rates of HF-related mortality (30% vs. 40%) but higher non-CV mortality (36% vs. 20%) compared to patients with reduced EF. CONCLUSIONS: Despite previous data suggesting benefit of serelaxin in AHF, treatment with serelaxin was not found to improve overall mortality or have an effect on any category of cause of death in RELAX-AHF-2. Careful adjudication of events in the serelaxin trials showed that older patients and those with preserved EF had fewer deaths from HF or sudden death and more deaths from other CV causes and from noncardiac causes. (Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF [RELAX-AHF-2]; NCT01870778)

NaxD is a deacetylase required for lipid A modification and Francisella pathogenesis

Modification of specific Gram-negative bacterial cell envelope components, such as capsule, O-antigen and lipid A, are often essential for the successful establishment of infection. Francisella species express lipid A molecules with unique characteristics involved in circumventing host defences, which significantly contribute to their virulence. In this study, we show that NaxD, a member of the highly conserved YdjC superfamily, is a deacetylase required for an important modification of the outer membrane component lipid A in Francisella. Mass spectrometry analysis revealed that NaxD is essential for the modification of a lipid A phosphate with galactosamine in Francisella novicida, a model organism for the study of highly virulent Francisella tularensis. Significantly, enzymatic assays confirmed that this protein is necessary for deacetylation of its substrate. In addition, NaxD was involved in resistance to the antimicrobial peptide polymyxin B and critical for replication in macrophages and in vivo virulence. Importantly, this protein is also required for lipid A modification in F. tularensis as well as Bordetella bronchiseptica. Since NaxD homologues are conserved among many Gram-negative pathogens, this work has broad implications for our understanding of host subversion mechanisms of other virulent bacteria

The MeerKAT international GHz tiered extragalactic exploration (MIGHTEE) survey

The MIGHTEE large survey project will survey four of the most well-studied extragalactic deep fields, totalling 20 square degrees to µJy sensitivity at Giga-Hertz frequencies, as well as an ultra-deep image of a single ∼1 deg2 MeerKAT pointing. The observations will provide radio continuum, spectral line and polarisation information. As such, MIGHTEE, along with the excellent multi-wavelength data already available in these deep fields, will allow a range of science to be achieved. Specifically, MIGHTEE is designed to significantly enhance our understanding of, (i) the evolution of AGN and star-formation activity over cosmic time, as a function of stellar mass and environment, free of dust obscuration; (ii) the evolution of neutral hydrogen in the Universe and how this neutral gas eventually turns into stars after moving through the molecular phase, and how efficiently this can fuel AGN activity; (iii) the properties of cosmic magnetic fields and how they evolve in clusters, filaments and galaxies. MIGHTEE will reach similar depth to the planned SKA all-sky survey, and thus will provide a pilot to the cosmology experiments that will be carried out by the SKA over a much larger survey volume